{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:07:33Z","timestamp":1789452453881,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-05147-2","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T10:01:56Z","timestamp":1721296916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-569X","authenticated-orcid":false,"given":"Rashid K.","family":"Sayyid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Chavarriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harkanwal","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian S.","family":"Wettstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Grace","family":"Cockburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"issue":"22","key":"5147_CR1","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1200\/JCO.22.02762","volume":"41","author":"JP Stein","year":"2023","unstructured":"Stein JP, Lieskovsky G, Cote R et al (2023) Radical cystectomy in the treatment of invasive bladder Cancer: long-term results in 1,054 patients. J Clin Oncol 41(22):3772\u20133781","journal-title":"J Clin Oncol"},{"issue":"6","key":"5147_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/bju.15627","volume":"129","author":"R Veeratterapillay","year":"2021","unstructured":"Veeratterapillay R, Geraghty R, Pandian R et al (2021) Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study. BJU Int 129(6):744\u2013751","journal-title":"BJU Int"},{"key":"5147_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"J Alfred Witjes","year":"2017","unstructured":"Alfred Witjes J, Lebret T, Comp\u00e9rat EM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71:462\u2013475","journal-title":"Eur Urol"},{"key":"5147_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupr\u00eat","year":"2021","unstructured":"Roupr\u00eat M, Babjuk M, Burger M et al (2021) European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 79:62\u201379","journal-title":"Eur Urol"},{"key":"5147_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/annonc\/mdr354","volume":"23","author":"F Cognetti","year":"2012","unstructured":"Cognetti F, Ruggeri EM, Felici A et al (2012) Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 23:695\u2013700","journal-title":"Ann Oncol"},{"key":"5147_CR6","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1200\/JCO.2010.34.4028","volume":"29","author":"WM Stadler","year":"2011","unstructured":"Stadler WM, Lerner SP, Groshen S et al (2011) Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 29:3443\u20133449","journal-title":"J Clin Oncol"},{"key":"5147_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","volume":"16","author":"CN Sternberg","year":"2015","unstructured":"Sternberg CN, Skoneczna I, Kerst JM et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N\u2009+\u2009M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16:76\u201386","journal-title":"Lancet Oncol"},{"key":"5147_CR8","doi-asserted-by":"crossref","unstructured":"Birtle AJ, Jones R, Chester J et al (2024) Improved Disease-Free Survival with Adjuvant Chemotherapy after Nephroureterectomy for Upper Tract Urothelial Cancer: final results of the POUT Trial. J Clin Oncol JCO2301659","DOI":"10.1200\/JCO.23.01659"},{"issue":"4","key":"5147_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/JU.0000000000000644","volume":"203","author":"V Margulis","year":"2020","unstructured":"Margulis V, Puligandla M, Trabulsi EJ et al (2020) Phase II trial of Neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high Grade Upper Tract Urothelial Carcinoma. J Urol 203(4):690\u2013698","journal-title":"J Urol"},{"issue":"8","key":"5147_CR10","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1200\/JCO.22.00763","volume":"41","author":"JA Coleman","year":"2023","unstructured":"Coleman JA, Yip W, Wong NC et al (2023) Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for patients with high-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol 41(8):1618\u20131625","journal-title":"J Clin Oncol"},{"issue":"4","key":"5147_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JE et al (2021) Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22(4):525\u2013537","journal-title":"Lancet Oncol"},{"issue":"2","key":"5147_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","volume":"85","author":"T Powles","year":"2024","unstructured":"Powles T, Assaf ZJ, Degaonkar V et al (2024) Updated overall survival by circulating Tumor DNA Status from the phase 3 IMvigor010 trial: adjuvant atezolizumab Versus Observation in muscle-invasive Urothelial Carcinoma. Eur Urol 85(2):114\u2013122","journal-title":"Eur Urol"},{"issue":"22","key":"5147_CR13","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE et al (2021) Adjuvant Nivolumab versus Placebo in muscle-invasive Urothelial Carcinoma. N Engl J Med 384(22):2102\u20132114","journal-title":"N Engl J Med"},{"issue":"6","key":"5147_CR14","first-page":"Suppl","volume":"41","author":"MD Galsky","year":"2023","unstructured":"Galsky MD, Witjes AA, Gschwend JE et al (2023) Extended follow-up results from the CheckMate 274 trial. J Clin Oncol 41(6):Suppl","journal-title":"J Clin Oncol"},{"issue":"4","key":"5147_CR15","first-page":"Suppl","volume":"42","author":"AB Apolo","year":"2024","unstructured":"Apolo AB, Ballman KV, Sonpavde GP et al (2024) AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. J Clin Oncol 42(4):Suppl","journal-title":"J Clin Oncol"},{"key":"5147_CR16","unstructured":"FDA approves nivolumab for adjuvant treatment of urothelial carcinoma (2024) https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma. Accessed on March 1"},{"key":"5147_CR17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"Savovi\u0107 Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"issue":"2","key":"5147_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 1(2):97\u2013111","journal-title":"Res Synth Methods"},{"issue":"7414","key":"5147_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"4","key":"5147_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383\u2013394","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"5147_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","volume":"53","author":"A Thornton","year":"2000","unstructured":"Thornton A, Lee P (2000) Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 53(2):207\u2013216","journal-title":"J Clin Epidemiol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05147-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05147-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05147-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:17:07Z","timestamp":1735852627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05147-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5147"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05147-2","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentations"}},{"value":"The authors declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"418"}}